A practical reference on PPARδ: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-19. Anything still debated is marked as such rather than presented as settled.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
cutting the civil list abolishing some unnecessary court expenses reducing ministers' salaries recalling former Murattian officers into the army reorganizing the army The new ruler, however, did not accept political and institutional reforms demandede by the liberals. Instead he propped up the police regime established by his predecessors and crushed any hint of revolt. However, unlike his forbears, Ferdinand II was aware of conditions in the outlying provinces and made official trips to visit them. The first came on 7 April 1833, when the king visited Calabria and surroundings, returning to the capital on May 6. During his visit he granted pardons, decreed bridges and roads, corrected arbitrary actions of public administrators and bestowed substantial relief to earthquake victims of the 8 March 1832 earthquake that damaged the Crati and Coraci basin. Before the outbreak of the revolutions of 1848, Calabria was the scene of uprisings, all of which were suppressed. The protagonists were from other parts of Italy, such as the Venetian Bandiera brothers, who arrived in 1844 to lend support to the Cosenza revolt. They were betrayed by one of their comrades, captured by the gendarmerie, and executed in August after a summary trial. Calabrians such as the Five Martyrs of Gerace (Michele Bello, Pietro Mazzoni, Gaetano Ruffo, Domenico Salvadori and Rocco Verduci) in 1847 tried to make the Gerace district rise up as part of the Mazzinian uprising in Reggio Calabria and Messina on 2 September 1847, were shot after the suppression of the uprising.
On 23 January 2026, Danish prime minister Mette Frederiksen visited Greenland to express support for the people and the island's self-governing government, following comments by US president Donald Trump indicating his willingness to annex the territory. Trump had previously discussed strengthening security in the Arctic region with NATO secretary general Mark Rutte. Both the Danish and Greenlandic governments have affirmed that the island's sovereignty is indisputable, but remain open to discussions on issues such as security and economic development. The crisis eased after Trump withdrew threats of force and new tariffs.
=== Role in innate immune response === When a pathogen invades, tissue resident macrophages are among the first cells to respond. Two of the main roles of the tissue resident macrophages are to phagocytose incoming antigen and to secrete proinflammatory cytokines that induce inflammation and recruit other immune cells to the site.
Sources: en.wikipedia.org
=== Growstones === Growstones, made from glass waste, have both more air and water retention space than perlite and peat. This aggregate holds more water than parboiled rice hulls. Growstones by volume consist of 0.5 to 5% calcium carbonate – for a standard 5.1 kg bag of Growstones that corresponds to 25.8 to 258 grams of calcium carbonate. The remainder is soda-lime glass.
== Naming conventions == Before reunification, Germany was divided between the Bundesrepublik Deutschland (Federal Republic of Germany; commonly known as West Germany) and the Deutsche Demokratische Republik (DDR; German Democratic Republic; commonly known as East Germany). Reunification was achieved by accession (Beitritt) of the German Democratic Republic to the Federal Republic of Germany, so Bundesrepublik Deutschland became the official name of reunified Germany. In East Germany, the terms Westdeutschland (West Germany) or westdeutsche Bundesrepublik (West German Federal Republic) were preferred during the 1950s and 1960s. This changed under its constitutional amendment in 1974, when the idea of a single German nation was abandoned by East Germany. As a result, it officially considered West Germans and West Berliners as foreigners. The initialism BRD (FRG in English) began to prevail in East German usage in the early 1970s, beginning in the newspaper Neues Deutschland. Other Eastern Bloc nations soon followed suit. In 1965, the West German Federal Minister of All-German Affairs, Erich Mende, had issued the "Directives for the Appellation of Germany", recommending avoiding the initialism BRD. On 31 May 1974, the heads of West German federal and state governments recommended always using the full name in official publications. From then on, West German sources avoided the abbreviated form, with the exception of left-leaning organisations which embraced it.
==== MeSH D12.776.624.776.355 – cyclin-dependent kinase inhibitor proteins ==== MeSH D12.776.624.776.355.100 – cyclin-dependent kinase inhibitor p15 MeSH D12.776.624.776.355.200 – cyclin-dependent kinase inhibitor p16 MeSH D12.776.624.776.355.300 – cyclin-dependent kinase inhibitor p18 MeSH D12.776.624.776.355.400 – cyclin-dependent kinase inhibitor p19 MeSH D12.776.624.776.355.500 – cyclin-dependent kinase inhibitor p21 MeSH D12.776.624.776.355.600 – cyclin-dependent kinase inhibitor p27 MeSH D12.776.624.776.355.700 – cyclin-dependent kinase inhibitor p57
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.